share_log

博拓生物(688767.SH)：将继续深耕聚焦POCT检测赛道

Botuo Biotech (688767.SH): Will continue to focus on POCT testing tracks

Gelonghui Finance ·  May 13 04:14

Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the company will continue to focus on the POCT testing circuit, give full play to the technology, product, quality and sales advantages that the company has accumulated over the years, and launch new products with higher cost performance, higher sensitivity, and closer to customer usage needs in colloidal gold technology. In terms of new technology platforms, efforts are being made to expand the variety of immunofluorescence products, increase the number of registration certificates for immunofluorescence products, further improve product quality through microfluidic control technology, and create new technology products with differentiated advantages. At the same time, the company strives to find targets that can form industrial collaboration and complementary advantages to help improve and expand the company's product lineup and enhance the company's overall competitiveness.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment